Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Negative interim data for Progenics

An unplanned early analysis on a subset of the 880 patients in PGNX's open label Phase III trial of GMK, a GM2 ganglioside

Read the full 231 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE